NDRG1 and colonic neoplasm: Moreover, we demonstrated XIST and its targets NDRG1 and SEMA6A to be significantly repressed in clinical samples (Fig. 5B2) and provided evidence for hypermethylation of NDRG1 and SEMA6A in colon cancer clinical samples (Fig. 5B3).